Literature DB >> 20063524

Morphologic, immunphenotypic and clinical discriminators between T-cell/histiocyte-rich large B-cell lymphoma and lymphocyte-predominant Hodgkin lymphoma.

Walid A Mourad1, Sheikha Al Thani, Abdelghani Tbakhi, Mohamed Al Omari, Yasser Khafaga, Mohamed Shoukri, Amr El Weshi, Mohamed Al Shabana, Adnan Ezzat.   

Abstract

BACKGROUND: Features of T-cell/histiocyte rich large B-cell lymphoma (THRLBCL) overlap with those of lymphocyte predominant Hodgkin lymphoma (LPHL). The two lymphomas may represent a spectrum of the same disease, and differentiation between the two can sometimes be difficult. We looked at histomorphologic, immunophenotypic and clinical information that may help differentiate the two entities.
METHODS: Cases of THRLBCL and LPHL were blindly reviewed and studied for histological pattern (nodular vs. diffuse), nuclear features and pattern of expression of CD20, CD30, CD57, epithelial membrane antigen (EMA) and Epstein-Barr virus (EBV). A score encompassing diffuse histology, high nuclear grade, CD20 single-cell pattern, CD30+, CD57-, EMA-, and EBV+ was estimated for the diagnosis of TCHRLBCL.
RESULTS: There were 58 cases, including 30 cases of TCHRLBL and 28 cases of LPHL. The median age was 36 years for TCHRLBCL and 21 years for LPHL (P = 0.0001). Three types of nuclei were identified (lymphocytic/histocytic, Reed-Sternberg and centroblast-like). The latter two high-grade nuclei were suggestive of TCHRLBCL. TCHRLBCL and LPHL, respectively, showed diffuse histology, 90% vs. 4% (P = 0.001), single CD20+ cells, 93% vs. 3.5% (P = 0.00004), CD30+ cells, 30% vs. 0% (P = 0.01), CD57+ cells, 41% vs. 93% (P = 0.008), EMA+ cells, 27% vs. 60% (P = 0.113), EBV+ cells, 24% vs. 0% (P = 0.117), high nuclear grade, 70% vs. 0% (P = 0.001), total score 2-7 (mean 4.68) vs. 0-2 (mean 0.72) (P = 0.001), high stage, 86% vs. 7% (P = 0.0001).
CONCLUSION: Our findings indicate that a combination of multiple parameters can help differentiate between the two diseases. Two cases originally diagnosed as LPHL were re-assigned the diagnosis of THRLBCL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 20063524     DOI: 10.1016/s1658-3876(08)50056-2

Source DB:  PubMed          Journal:  Hematol Oncol Stem Cell Ther


  2 in total

1.  Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease?

Authors:  Sylvia Hartmann; Claudia Döring; Christina Jakobus; Benjamin Rengstl; Sebastian Newrzela; Thomas Tousseyn; Xavier Sagaert; Maurilio Ponzoni; Fabio Facchetti; Chris de Wolf-Peeters; Christian Steidl; Randy Gascoyne; Ralf Küppers; Martin-Leo Hansmann
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

2.  Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells.

Authors:  Rania M Seliem; Judith A Ferry; Robert P Hasserjian; Nancy L Harris; Lawrence R Zukerberg
Journal:  J Hematop       Date:  2011-07-23       Impact factor: 0.196

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.